GANX
Gain Therapeutics, Inc.
$1.69
-0.59%
$72.1M
No data for this timeframe.
Vol
Market Cap$72.1M
Cap SizeMicro Cap
Inst. Holders5 funds
Inst. Value$2.4M
Inst. Activity0 buys / 1 sells
Reddit Sentiment54° Neutral
SEC Reports3
Press Releases2
Recent Activity
Jun 9, 2026
short_volume
Short Volume: GANX — 73.9% short (0.6M / 0.8M)
Short: 564,149 | Exempt: 5,895 | TRF Vol: 763,378 | Short Ratio: 73.9% | Off-exchange volume (dark p
May 26, 2026
SEC
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 in Parkins
8-K — Impact 5/10
May 11, 2026
SEC
Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat is marginal for a pr
PRESS-RELEASE — Impact 4/10
Apr 28, 2026
SEC
Gain Therapeutics filed definitive additional proxy materials (DEFA14A) for its 2026 annual meeting, recommending stockh
DEFA14A — Impact 3/10
Mar 24, 2026
Insider
Fuggetta Gianluca sold 50,000 shares
See Remark @ $0.00 ($0.00)
Mar 24, 2026
Insider
Mack Gene sold 200,000 shares
CEO, President @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEAR_EXIT
17,400 shares ($56.0K)
Inst.
MORGAN STANLEY — DOUBLED
155,675 shares ($275.5K)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$7.20 (Dec 2025)
Current $1.65
Low $5.00
Median $8.00
High $8.00
5 analysts
$5.00
$8.00
Analyst Ratings
4Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▼ -2.3% | $-0.18 — $-0.13 | 21% YoY | 4 |
| Next Q | $-0.16 ▲ +3.6% | $-0.21 — $-0.13 | -5% YoY | 4 |
| Current FY | $-0.60 | $-0.79 — $-0.51 | 1% YoY | 4 |
| Next FY | $-0.60 ▲ +3.7% | $-0.74 — $-0.48 | 0% YoY | 3 |
Latest Reports
BULLISH
8-K
5/10
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 in Parkins
May 26, 2026
NEUTRAL
PRESS-RELEASE
4/10
Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat is marginal for a pr
May 11, 2026
MIXED
Press
6/10
Gain Therapeutics reported financial results for 2025, showing a slight reduction in net loss to $20.2M from $20.4M in 2
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.8M | DOUBLED |
| MORGAN STANLEY | $475.2K | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $56.0K | NEAR_EXIT |
| BANK OF AMERICA CORP | $12.6K | — |
| WELLS FARGO & COMPANY/MN | $8.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 24, 2026 | Fuggetta Gianluca | A | $0.00 |
| Mar 24, 2026 | Mack Gene | A | $0.00 |
Reddit Sentiment
54°▲
Neutral
Bearish
Neutral
Bullish
5 institutional holders with $2.4M total value (741,450 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 569,901 | $1.8M | 76.9% | DOUBLED +109.6% |
| 2 | MORGAN STANLEY | 147,591 | $475.2K | 19.9% | DOUBLED +103.5% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 17,400 | $56.0K | 2.3% | NEAR_EXIT -86.2% |
| 4 | BANK OF AMERICA CORP /DE/ | 3,908 | $12.6K | 0.5% | — |
| 5 | WELLS FARGO & COMPANY/MN | 2,650 | $8.5K | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 126,100 | 17,400 | -86.2% | $56.0K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 76,512 | 155,675 | +103.5% | $275.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 32,635 | 140,677 | +331.1% | $249.0K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 94,000 | 126,100 | +34.1% | $223.2K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 254,990 | 534,352 | +109.6% | $961.8K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 94,000 | — | $169.2K | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 177,075 | 254,990 | +44.0% | $487.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 27,912 | 36,119 | +29.4% | $69.0K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 4,800 | 88,512 | +1744.0% | $191.2K | 2024-Q4 |
| UBS Group AG | DOUBLED | 8,455 | 35,227 | +316.6% | $76.1K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 27,912 | — | $60.3K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 53,264 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | ADD | 3,300 | 4,800 | +45.5% | $8.5K | 2024-Q3 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | Fuggetta Gianluca | See Remark | A | 50,000 | $0.00 | $0.00 |
| Mar 24, 2026 | Mack Gene | CEO, President | A | 200,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
BULLISH
8-K
5/10
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of
May 26, 2026
NEUTRAL
PRESS-RELEASE
4/10
Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat
May 11, 2026
NEUTRAL
DEFA14A
3/10
Gain Therapeutics filed definitive additional proxy materials (DEFA14A) for its 2026 annual meeting,
Apr 28, 2026
Historical analyst distribution (last covering-analyst action Dec 2025): 91% buy across 11 analysts — 4 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$7.20 mean target (Dec 2025)
$5.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.65 |
| Target Low | $5.00 |
| Target Mean | $7.20 |
| Target Median | $8.00 |
| Target High | $8.00 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.18 | $-0.13 | 21.0% | -2.3% | — | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.16 | $-0.21 | $-0.13 | -5.0% | +3.6% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.60 | $-0.79 | $-0.51 | 1.2% | +0.4% | 1↑ 1↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.60 | $-0.74 | $-0.48 | 0.4% | +3.7% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.150 | |
| 7d ago | $-0.140 | -0.010 |
| 30d ago | $-0.147 | -0.003 |
| 60d ago | $-0.150 | |
| 90d ago | $-0.163 | +0.013 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
54°
Neutral
Bearish
Neutral
Bullish
32 mentions
10 bullish
7 bearish
21 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 26, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 4 | 44° Neutral | 0 | 1 | 4 |
| May 20, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| May 12, 2026 | 3 | 36° Cool | 0 | 2 | 3 |
| May 12, 2026 | 3 | 36° Cool | 0 | 2 | 3 |
| May 6, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| May 6, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 30, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 30, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 29, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Apr 29, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 18, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 18, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
GANX — Honest Look at the Risk Profile. This Is a Binary Clinical Bet With a Ticking Cash Clock.
▲ 1
💬 1
⚡ 0.5
GANX — The Catalyst Timeline For the Rest of 2026
▲ 1
💬 1
⚡ 0.5
GANX Q1: Net loss widened. R&D and G&A up. Timelines intact (Q2 IND, Q3 Phase 2, Q4 more data). That's the real story.
▲ 1
💬 1
⚡ 0.2
World Parkinson's Congress right after. Back to back conferences maximize exposure for a small biotech.
▲ 1
💬 0
⚡ 0.5
MJFF backing + Silverstein backing + conference presentations + biomarker data. GANX checking boxes for a clinical stage name.
▲ 1
💬 1
⚡ 0.5
GANX breakdown: GT-02287 (Parkinson's, GBA1), Phase 1b biomarker data (81% GluSph drop), now two major conferences in May.
▲ 1
💬 1
⚡ 0.5
$GANX Announcement - Currently Down 23%
▲ 1
💬 1
⚡ 0.5
Jun 9, 2026
short_volume
Short Volume: GANX — 73.9% short (0.6M / 0.8M)
Short: 564,149 | Exempt: 5,895 | TRF Vol: 763,378 | Short Ratio: 73.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: GANX — 62.4% short (0.3M / 0.5M)
Short: 329,803 | Exempt: 0 | TRF Vol: 528,189 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
GANX Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
<p>BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology
Apr 24, 2026
other
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
<p>BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnolo
Mar 26, 2026
earnings
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
<p>BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnolo
Mar 19, 2026
other
Gain Therapeutics to Present at the 38th Annual ROTH Conference
<p>BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnolo
Mar 19, 2026
earnings_calendar
GANX Q4 2025 Earnings After Market Close — 2026-03-19
Mar 18, 2026
fda
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
<p align="center"><em>Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with